Abstract
Amongst all currently used drugs in the field of cancer therapy, the most prominent group of agents which induce DNA, damage both directly or indirectly. Intuitively DNA should not be a perfect target for relatively unspecific small molecular weight drugs. However, the current understanding is that not damage per se but cellular response to DNA damage induced by antitumor agents is responsible for their specific targeted effect towards cancer cells in comparison to the normal cells. DNA damaging chemotherapeutics include compounds with diferent activities namely: directly or indirectly induce DNA strand breaks, covalently modify DNA bases, change the chromatin structure and topology by inhibiting chromatin-modifying enzymes. In this special issue of Current Medicinal Chemistry entitled....
Current Medicinal Chemistry
Title:Editorial: DNA Damage as a Strategy for Anticancer Chemotherapy
Volume: 24 Issue: 15
Author(s): Maria Bozko, Andrzej Bozko, Tim Scholta, Nisar P. Malek and Przemyslaw Bozko*
Affiliation:
- Department of Internal Medicine I, Eberhard Karls University Tubingen Tubingen,Germany
Abstract: Amongst all currently used drugs in the field of cancer therapy, the most prominent group of agents which induce DNA, damage both directly or indirectly. Intuitively DNA should not be a perfect target for relatively unspecific small molecular weight drugs. However, the current understanding is that not damage per se but cellular response to DNA damage induced by antitumor agents is responsible for their specific targeted effect towards cancer cells in comparison to the normal cells. DNA damaging chemotherapeutics include compounds with diferent activities namely: directly or indirectly induce DNA strand breaks, covalently modify DNA bases, change the chromatin structure and topology by inhibiting chromatin-modifying enzymes. In this special issue of Current Medicinal Chemistry entitled....
Export Options
About this article
Cite this article as:
Bozko Maria , Bozko Andrzej , Scholta Tim , Malek P. Nisar and Bozko Przemyslaw *, Editorial: DNA Damage as a Strategy for Anticancer Chemotherapy, Current Medicinal Chemistry 2017; 24 (15) . https://dx.doi.org/10.2174/092986732415170630115722
DOI https://dx.doi.org/10.2174/092986732415170630115722 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurotrophins in the Lower Urinary Tract: Becoming of Age
Current Neuropharmacology Pharmaceutical Applications of Graphene-based Nanosheets
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Cancer Biomarkers from Bench to Bedside)
Current Cancer Drug Targets The Kinase Inhibitor Imatinib - An Immunosuppressive Drug?
Current Cancer Drug Targets Short-Chain Fatty Acid Inhibitors of Histone Deacetylases: Promising Anticancer Therapeutics?
Current Cancer Drug Targets Neuroimaging of Cancer Patients for Psychosocial Support and Patient Care
Current Medical Imaging Garlic [Allium sativum]: A Review of its Potential Use as an Anti-Cancer Agent
Current Cancer Drug Targets New Prospects for Nelfinavir in Non-HIV-Related Diseases
Current Molecular Pharmacology G4 Aptamers: Trends in Structural Design
Mini-Reviews in Medicinal Chemistry NOTCH Signaling as a Novel Cancer Therapeutic Target
Current Cancer Drug Targets Tracking Stem Cell Therapy in the Myocardium: Applications of Positron Emission Tomography
Current Pharmaceutical Design Anticancer Hybrids- A Patent Survey
Recent Patents on Anti-Cancer Drug Discovery Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion
Current Vascular Pharmacology CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies
Current Cancer Drug Targets Expression Microarray Proteomics and the Search for Cancer Biomarkers
Current Genomics Activity Based Chemical Proteomics: Profiling Proteases as Drug Targets
Current Drug Discovery Technologies Preparation, Photoluminescence and Antimicrobial Activity of Loracarbef and its Various Complexes
Current Analytical Chemistry A Current Update on the Use of Alpha Lipoic Acid in the Management of Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemoprevention Gene Therapy (CGT): Novel Combinatorial Approach for Preventing and Treating Pancreatic Cancer
Current Molecular Medicine Multiple Roles of Annexin A2 in Post-Transcriptional Regulation of Gene Expressio
Current Protein & Peptide Science